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A B S T R A C T   
Stenotrophomonas maltophilia (S. maltophilia) is a Gram-negative, multidrug-resistant organism that both oppor-
tunistically infects the bloodstream and leads to pneumonia in immunosuppressed patients, including those with 
hematologic malignancies. In patients with severe respiratory failure, venovenous extracorporeal membrane 
oxygenation (VV ECMO) can stabilize the respiratory status. However, whether ECMO in patients with hema-
tologic malignancies improves the clinical outcomes is still controversial because ECMO increases the risk of the 
exacerbation of sepsis and bleeding. We report a case of a 46-year-old man with Stenotrophomonas maltophilia 
hemorrhagic pneumonia acquired during consolidation chemotherapy for acute myeloid leukemia in whom VV 
ECMO lead to a good clinical outcome. The stabilization of his respiratory status achieved with VV ECMO 
allowed time for trimethoprim-sulfamethoxazole antibiotic therapy to improve the pneumonia. We suggest the 
background of patients, including comorbidities and general conditions, should be taken into account when 
considering the clinical indications of ECMO.   
1. Introduction 
Stenotrophomonas maltophilia (S. maltophilia) is a Gram-negative, 
obligate, rod-shaped, multidrug-resistant aerobe that has been isolated 
from aqueous-associated sources in both nosocomial and community 
settings [1,2]. Although it is of low virulence, it acts as an opportunistic 
pathogen, leading to severe sepsis and pneumonia by action of a 
protease-initiated insult of lung tissue leading to hemorrhage [4,5] in 
immunosuppressed patients, including those with hematologic malig-
nancies [3]. Hemorrhagic pneumonia caused by S. maltophilia in he-
matologic malignancies usually has a fatal course [6]. 
Extracorporeal gas exchange is a technique that enables gas ex-
change by the extracorporeal circulation of blood through an artificial 
organ [7]. Venovenous extracorporeal membrane oxygenation (VV 
ECMO) is a mechanical-assisted therapy for the extracorporeal gas ex-
change in patients with severe respiratory failure, which oxygenates and 
removes carbon dioxide from the blood [8,9]. VV ECMO has been re-
ported as successful in limited case studies for acute pneumonia with 
hematologic malignancies, including in S. maltophilia hemorrhagic 
pneumonia associated with hematologic malignancies [10,11]. 
Here, we present a case of S. maltophilia hemorrhagic pneumonia in a 
45-year-old man treated with VV ECMO during consolidation chemo-
therapy for acute myeloid leukemia. After VV ECMO therapy, he fully 
regained his functional status and was commenced on subsequent 
consolidation chemotherapy and allogenic hematopoietic stem cell 
transplantation. 
This study was approved by the Institutional Review Board of Kur-
ashiki Central Hospital and was conducted according to the principles of 
the Declaration of Helsinki. In accordance with the ethical concerns of 
the Institutional Review Board of Kurashiki Central Hospital, patient 
confidentiality was protected by removing or masking patient identi-
fiers, and informed consent was obtained from the patient for the pub-
lication of this case report and accompanying images. 
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2. Case presentation 
A 45-year-old man was referred to and admitted to our hospital after 
visiting a local clinic with complaints of general malaise, fever and a 2- 
week history of purpura. Laboratory analysis revealed pancytopenia. On 
admission, laboratory data revealed leukopenia (1.4 × 109/L), anemia 
(hemoglobin 4.5 g/dL), and thrombocytopenia (undetectable). 
Computed tomography (CT) showed a diffusely increased bone marrow 
concentration, but did not show liver or splenic enlargement. Bone 
marrow aspiration was unsuccessful, leading to bone marrow biopsy, 
which revealed acute panmyelosis with myelofibrosis, a rare subtype of 
acute myeloid leukemia. Induction therapy (idarubicin hydrochloride 
12 mg/m2 for three days and cytosine arabinoside 100 mg/m2/day for 
seven days) was started on day 8. His clinical course is shown in Fig. 1. 
Cefozopran treatment for febrile neutropenia was started on day 2. Left 
cheek cellulitis appeared on day 20, which failed to respond to cefozo-
pran treatment, and was thereafter switched to meropenem/vancomy-
cin treatment on day 29. After confirming blood cell recovery and 
improved cellulitis, antibiotic therapy was switched to levofloxacin on 
day 38. Bone marrow aspiration failed again at the end of the induction 
therapy. Peripheral blood cell count was within normal limits, and 
Wilm’s tumor 1 mRNA count decreased from 37,000 copies/μg mRNA 
(reference level <50 copies/μg RNA) on day 3–150 copies/μg mRNA on 
day 38. We determined that he had achieved hematological complete 
remission, and consolidation therapy (cytosine arabinoside 2000 mg/ 
m2 × 2/day for five days) was started. Because of febrile neutropenia on 
day 49, we switched levofloxacin to cefozopran. Despite antibiotic 
therapy, he showed sustained hyperthermia again on day 54. A blood 
culture test was performed, and the indwelling central venous catheter 
was removed. A chest radiograph on day 56 showed pneumonia in the 
entire right lung field. We switched treatment from cefozopran to mer-
openem and amikacin for possible pseudomonas aeruginosa pneumonia, 
which was ineffective. He was transferred to the intensive care unit 
(ICU) on the same day and underwent intubation on day 57. Both blood 
and sputum cultures revealed S. maltophilia, and trimethoprim- 
sulfamethoxazole (SMX-TMP) was administered, for which 
S. maltophilia was susceptible to, in addition to levofloxacin, ceftazi-
dime, and minocycline. Hematic tracheal aspirates were reported on 
around day 60. 
Intravenous granulocyte-colony stimulating factor in combination 
with SMX-TMP was administered for febrile neutropenia. As the neu-
tropenia resolved, his ventilator condition gradually deteriorated 
further from day 63. Airway pressure-release ventilation plus intermit-
tent prone positioning was initiated on day 66, which failed to improve 
his respiratory failure. PaO2/FiO2 was 69.5 with an FiO2 of 0.85 (PaCO2 
40 mmHg) and a respiratory rate of 20; a positive end-expiratory pres-
sure (PEEP) of 14; and a peak inspiratory pressure (PIP) of 27 cmH2O. 
Chest CT showed massive consolidation in both lung fields and opacities 
around them. During this period, the use of catecholamines was grad-
ually reduced. According to acute respiratory distress syndrome (ARDS) 
criteria [12], the patient met each criterion and was considered to have 
severe ARDS. Bronchoalveolar lavage showed cell counts of 600/μL 
(neutrophils, 59%; lymphocytes, 31%; atypical lymphocytes, 2%; and 
macrophages, 8%). In addition, both blood and sputum cultures yielded 
negative, which suggested antibiotic therapy with SMX-TMP was suc-
cessful. Due to high ventilator pressures and high oxygen demand, VV 
ECMO was considered, and after careful evaluation was initiated (day 
68, day 12 of invasive ventilation). We obtained 4.2 L/min of blood flow 
with 5 L/min of sweep gas, and the ventilator setting was lowered to an 
FiO2 of 0.4, a PIP of 20 cmH2O, and a PEEP of 10 cmH2O for resting the 
lungs. After lowering the ventilator pressure, the whole right lung and 
part of the left lung were observed as collapsed, and ventilation and 
oxygenation became completely VV ECMO-dependent. Tracheotomy 
was performed on day 71, and he was partially awakened. His lungs 
gradually opened up while regaining spontaneous breathing and active 
mobilization of bronchial secretions. On day 79, the patient was weaned 
off VV ECMO and was subsequently treated with mechanical ventilation 
support. Bilateral pulmonary infiltration improved after antibiotic 
therapy and ventilation therapy including VV ECMO (Fig. 2). 
Biphasic positive airway pressure was weaned on day 88, and oxygen 
supplementation was discontinued on day 131. He was discharged from 
the hospital on day 145, with a markedly improved pneumonia on chest 
Fig. 1. The clinical course. C-reactive pro-
tein and PaO2/FiO2 ratio were improved by 
both antibiotic therapy and ECMO therapy. 
Abbreviations: IDR, idarubicin hydrochlo-
ride; Ara-C, cytosine arabinoside; CAZ, cef-
tazidime; CRP, C-reactive protein; CZOP, 
cefozopran; MEPM, meropenem; VCM, van-
comycin; LVFX, levofloxacin; AMK, amika-
cin; SMX/TMP, sulfamethoxazole- 
trimethoprim; FLCZ, fluconazole; MCFG, 
micafungin; APRV, airway pressure-release 
ventilation; VV ECMO, venovenous extra-
corporeal membrane oxygenation; BIPAP, 
biphasic positive airway pressure; CRRT, 
continuous renal replacement therapy.   
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CT. Additional consolidation chemotherapy was postponed until he 
recovered his physical strength. After he fully regained his functional 
status, he received subsequent consolidation chemotherapy and allo-
genic hematopoietic stem cell transplantation. At the time of writing, he 
maintains in complete remission. 
3. Discussion 
The isolation rate of S. maltophilia is increasing due to recent de-
velopments in respiratory management and medical devices because 
S. maltophilia has the ability to spread and colonize along the respiratory 
tract and medical devices [1,2]. Host risk factors, including hematologic 
malignancies, an immune compromised state, the use of broad-spectrum 
antibiotics, and combination therapy with three or more antibiotics, 
have also been investigated [13]. In our case, we hypothesized that 
hematological malignancies and therapy with multiple antibiotics, 
including cefozopran, meropenem, levofloxacin, and vancomycin, may 
have resulted in S. maltophilia pneumonia. StmPr1 protease produced by 
S. maltophilia has degradative and cytotoxic actions, which leads to lung 
tissue damage and inflammation. [4,5]. Hemorrhagic pneumonia 
caused by S. maltophilia progresses rapidly and can be fatal [6]. 
SMX-TMP is the antibacterial treatment of choice against 
S. maltophilia. However, its efficacy remains controversial for patients 
with hemorrhagic pneumonia because of its rapidly progressive course. 
In earlier case reports, treatments for S. maltophilia hemorrhagic pneu-
monia using polymyxin [14] and fluoroquinolone [15] in combination 
with SMX-TMP were successful. However, these studies are limited by 
their small patient populations, leaving the efficacy of these regimens 
unclear. 
The mortality of acute pneumonia for patients with hematologic 
malignancies is high compared to patients without [16]. The number of 
patients requiring ICU treatment over the last decade has increased with 
the development of chemotherapy for hematological malignancies and 
its resulting expansion of indications for chemotherapy [17,18]. In 
contrast, the mortality of patients who require mechanical ventilation 
for pneumonia associated with the treatment of hematological malig-
nancies is still high at approximately 70% [18]. Patient factors that in-
fluence treatment resistance include neutropenia, fungal infections, 
sepsis, and the treatment responsiveness to underlying hematological 
malignancies [19]. 
The ICU treatment of hemorrhagic pneumonia due to S. maltophilia 
associated with hematological malignancies is challenging. Therefore, 
strict patient selection is required when considering whether ECMO is 
clinically appropriate in each patients. The CESAR randomized control 
trial has demonstrated the effectiveness of ECMO for ARDS [20]. In 
contrast, the effectiveness of ECMO for hematologic malignancies is yet 
to be clarified. In addition, the 6-month survival of patients on ECMO 
due to respiratory failure associated with hematological malignancies 
was as low as 25% [21]. 
Some intensive care physicians are hesitant with administering 
ECMO because of the risk leading to the exacerbation of infection, sepsis, 
and ICU-acquired weakness [21,22]. While this debate continues, our 
stance is to consider ECMO for patients with acute reversible respiratory 
failure, even those with hematologic malignancies and of immuno-
compromised status, if they meet the following criteria: (1) Infectious 
pneumonia with an available evidence-based antibiotic treatment, (2) A 
potentially curable hematological malignancy, (3) No diagnosis of 
chronic respiratory disease and active uncontrollable bleeding, (4) The 
patient is less 65 years old, (5) No recent history of a bone marrow 
transplant. 
Pneumonia with an available evidence-based antibiotic treatment 
and a potentially curable hematological malignancy are essential 
because ECMO is primarily for the stabilization of respiratory status. In 
contrast to hematologic malignancies, ARDS associated with bone 
marrow transplantation is a contraindication of ECMO. We have expe-
rienced many patients who experienced ARDS following bone marrow 
transplantation and developed pulmonary fibrosis, and patients who 
have recently received bone marrow transplantation are defined as a 
contraindication to ECMO in our medical department, which is consis-
tent with data from the ELSO registry [23]. Patients aged 65 and over 
with chronic respiratory failure are contraindications for ECMO use in 
the earlier literature [24,25]. Age is an important prognostic factor in 
hematological malignancies as a result of the substantial physiological 
demands of chemotherapy in patients of advanced age. Overall survival 
in elderly patients aged 65 or older with acute myeloid leukemia is less 
than 10%, which is lower than that of younger patients due to the dif-
ferences in both tumor and patient characteristics [26,27]. As ECMO is 
used for the primary purpose of life support, ECMO should not be used in 
elderly patients with a diagnosis of acute myeloid leukemia and a poor 
prognosis for long-term survival. In our case, inclusion factors of the 
patient being in complete remission, diagnosis of S. maltophilia infection, 
and in hemostasis were met, leading to the commencement of VV ECMO. 
Thereafter, we lowered the ventilator settings to prevent the progression 
of ventilator-induced lung injury. In addition, awake management and 
mobilization prevented ICU-acquired weakness, and maintenance of 
spontaneous breathing assisted clearance of bronchial secretions and 
improvement of the pneumonia. 
Hemorrhagic pneumonia caused by S. maltophilia can be potentially 
resolved with SMX-TMP. However, death due to respiratory failure may 
occur because of its rapid progression, and VV ECMO is one method of 
stabilizing the patient until recovery is achieved. Awake management 
and mobilization prevents ICU-acquired weakness, and maintenance of 
spontaneous breathing assists clearance of bronchial secretions and 
improvement of pneumonia. Note that VV ECMO use should be limited 
to the patients with the criteria described above. VV ECMO is not clin-
ically appropriate in all patients with hematological malignancies who 
Fig. 2. Bilateral pulmonary infiltration improved after antibiotic therapy and ventilation therapy including venovenous extracorporeal membrane oxygenation 
(Chest radiographs on days 56, 68, and 79). Abbreviations: VV ECMO, venovenous extracorporeal membrane oxygenation; ICU; intensive care unit. 
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experience severe respiratory failure. 
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